CIS: Clinical Trials

2 completed, 1 terminated, 1 withdrawn. 2 Phase 1, 1 Phase 4.

By phase and status

Phase	Trials	Status
Phase 1	2	Completed 2
Phase 4	1	Withdrawn 1

Follow CIS: new trials by email Literature Review of CIS trials Research Report on CIS

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose. nadofaragene firadenovec - Bladder Cancer, Ta/T1	Phase 4	Withdrawn	Ferring Pharmaceuticals		2024-06-17	2024-11-22
A Prospective Registry to Assess the Effectiveness and Local Tolerability of Intravesical Valrubicin in Subjects With Non-muscle Invasive Bladder Cancer (NMIBC) Bladder Cancer, CIS		Terminated	Endo USA Inc., a Keenova Therapeutics Company	15	2011-05-01	2015-06-12
Study To Determine The Maximum Range of Light Doses At Two HPPH Doses With Acceptable Normal Tissue Toxicity For PDT Treatment Of High Grade Dysplasia,CIS or Early Adenocarcinoma In Barrett's Esophagus HPPH - Barrett's Esophagus, CIS	Phase 1	Completed	Roswell Park Cancer Institute	18	2003-03-01	2014-12-02
Study of Photodynamic Therapy (PDT) Using HPPH in Barrett's Esophagus HPPH - Barrett's Esophagus, CIS	Phase 1	Completed	Roswell Park Cancer Institute	18	2000-08-01	2014-01-13

Narrower conditions

Barrett Esophagus (2)  ·  Urinary Bladder Neoplasms (2)  ·  Non-Muscle Invasive Bladder Neoplasms (1)

Broader conditions

Neoplasms (4)  ·  Digestive System Diseases (2)  ·  Esophageal Diseases (2)  ·  Female Urogenital Diseases (2)  ·  Female Urogenital Diseases and Pregnancy Complications (2)  ·  Gastrointestinal Diseases (2)  ·  Male Urogenital Diseases (2)  ·  Neoplasms by Site (2)  ·  Precancerous Conditions (2)  ·  Urinary Bladder Diseases (2)  ·  Urogenital Diseases (2)  ·  Urogenital Neoplasms (2)  ·  Urologic Diseases (2)  ·  Urologic Neoplasms (2)  ·  Carcinoma (1)

Interventions

2-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a (2)

Sponsors

Roswell Park Cancer Institute (2)  ·  Endo USA Inc., a Keenova Therapeutics Company (1)  ·  Ferring Pharmaceuticals (1)

Countries

United States (4)

Top investigators

Hector Nava, MD (2)  ·  Todd Kirby, PhD (1)